Back to results
US 2013/0172239 A1Published application
Solid compositions
AssigneeAbbVie Inc.
InventorsYi Gao, Geoff G.Z. Zhang
Life of this patent
Estimating the term…
Abstract
The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
Claims19
A solid composition comprising
- an HCV inhibitor selected from telaprevir, BI-201335, TMC-435, vaniprevir, MK-5172, asunaprevir, daclatasvir, danoprevir, setrobuvir, tegobuvir, GS-9451, mericitabine, IDX-184, filibuvir, PSI-7977, PSI-352938, BIT-225, boceprevir, GS-5885 or GS-9256,
- a pharmaceutically acceptable hydrophilic polymer, and
- optionally a pharmaceutically acceptable surfactant.
Dependencies are inferred from the claim text.